Patients with rare diseases in India, like Saifullah Khalidi with spinal muscular atrophy (SMA), struggle to afford ...

Patient advocates push for generic drug production to treat rare diseases, facing patent barriers and high costs.

The Cas nuclease market is on an upward trajectory, forecasted to grow from $2.75 billion in 2023 to $3.27 billion in 2024, at a CAGR of 18.9%. Key drivers include the rapid advancements in genome ...

Reliance Power, Nykaa, 3M India, Sula Vineyards, BASF India, Natco Pharma, and Rattanindia Enterprises are among other firms ...

Just over a year ago, New Zealand customs officials started to intercept batches of injectable medications labelled Fitaro ...

The "CC Chemokine Receptor Type 5 Market Report 2024" report has been added to ResearchAndMarkets.com's offering.The CC ...

In our view, this is a reflection of India’s growing economic heft ... Reshma Kewalramani, CEO of Vertex Pharmaceuticals; Satya Nadella CEO of Microsoft Corporation; Jayshree V.

In the trading week from November 4th to 8th, experts opinion is between volatile to bearish in Dow Jones, S&P 500, and ...

Abry Partners, a Boston-based private equity firm, and BHMS Investments, LP, a Connecticut-based private equity firm, have completed the sale of Innovisk to Ryan Specialty , a leading international ...

PrivateThe Q2 earnings season has crossed the peak and is now nearing the end of the season. Out of 4699 companies listed on exchanges, 1852 companies have already declared their quarterly financials ...